Rotavirus Vaccine Market Report 2026

Rotavirus Vaccine Market Overview

• Rotavirus Vaccine market size has reached to $10.14 billion in 2025 • Expected to grow to $16.45 billion in 2030 at a compound annual growth rate (CAGR) of 10.1% • Growth Driver: Impact Of Rising Birth Rates On Rotavirus Vaccine Market Growth • Market Trend: Oral-Dosing Applicators Enhance Rotavirus Vaccine Delivery And Compliance • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Rotavirus Vaccine Market?

The rotavirus vaccine refers to a vaccine designed to protect against rotavirus infections, which are a common cause of severe diarrhea and gastroenteritis in infants and young children. This vaccine is administered orally and contains live attenuated or inactivated strains of the rotavirus to stimulate an immune response and provide immunity against the virus. The main types of rotavirus vaccine include rotarix, rotateq, rotavac, rotavin-M1, lanzhou lamb, and others. Rotarix is a live attenuated oral rotavirus vaccine designed to protect infants from rotavirus gastroenteritis, which can cause severe diarrhea and dehydration. The application are categorized into adult and pediatric for end users including hospitals, clinics, and academic research.

What Is The Rotavirus Vaccine Market Growth Forecast?

The rotavirus vaccine market size is expected to see rapid growth in the next few years. It will grow to $16.45 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing demand for universal pediatric vaccination, expansion of combination vaccine development, growing investments in vaccine manufacturing capacity, rising focus on global immunization coverage, increasing collaboration with public health agencies. Major trends in the forecast period include increasing expansion of pediatric immunization programs, rising adoption of oral vaccine formulations, growing focus on vaccine cold chain optimization, expansion of public health vaccination initiatives, enhanced surveillance of rotavirus infections.

Global Rotavirus Vaccine Market Segmentation

1) By Type: Rotarix, RotaTeq, Rotavac, Rotavin-M1, Lanzhou lamb, Other Types 2) By Application: Adult, Pediatric 3) By End Users: Hospitals, Clinics, Academic Research

What Is The Driver Of The Rotavirus Vaccine Market?

The rising birth rates are expected to propel the growth of the rotavirus vaccine market going forward. Birth rates refer to the number of live births per 1,000 people in a population over a specific period, typically expressed annually. Birth rates are influenced by higher economic stability and growth, as well as supportive policies such as parental leave, child benefits, and childcare subsidies. The use of rotavirus vaccines helps to reduce the incidence of severe rotavirus gastroenteritis in infants, thereby improving child health outcomes and reducing healthcare costs associated with rotavirus infections. For instance, in January 2023, according to a report published by the Centers for Disease Control and Prevention, a US-based national public health organization, the United States witnessed a 1% increase in registered births, totaling 3,664,292, compared to the previous year. Therefore, rising birth rates will drive the growth of the rotavirus vaccine industry.

Key Players In The Global Rotavirus Vaccine Market

Major companies operating in the rotavirus vaccine market are Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, GlaxoSmithKline plc, Daiichi Sankyo Company Limited, Serum Institute of India Private Limited, Sinovac Biotech Ltd. , SK Chemicals Co Ltd, Bharat Biotech International Limited, Walvax Biotechnology Co. Ltd., Indian Immunologicals Limited, PT Bio Farma, KFF Inc., Panacea Biotec Limited, Sanyou Biopharmaceuticals Co. Ltd., Inovio Pharmaceuticals Inc., Hilleman Laboratories Private Limited, China National Biotec Group Corporation, Vabiotech, Lanzhou Institute of Biological Products Co. Ltd., Nuvonis Pharmaceuticals Inc., Chengdu Institute of Biological Products Co. Ltd

Global Rotavirus Vaccine Market Trends and Insights

Major companies operating in the rotavirus vaccine market are adopting oral-dosing applicators to enhance vaccine delivery efficiency and improve patient compliance. Oral-dosing applicators are medical devices designed to administer liquid medications or vaccines directly into the mouth, ensuring accurate dosage and ease of use, especially for infants and young children. For instance, in June 2025, Micron Biomedical, a U.S.-based biotechnology company, and Emory University, a U.S.-based private university, launched a first-in-human clinical trial of the inactivated rotavirus vaccine CC24 delivered via a dissolvable microarray patch. This patch is thermostable (reduces cold chain dependence), enables self-administration, and produces no sharps waste. This innovation promises greater vaccine access in low-resource settings, although regulatory pathways remain untested, and scale-up risks may delay broad adoption in the rotavirus vaccine market.

What Are Latest Mergers And Acquisitions In The Rotavirus Vaccine Market?

In June 2024, Murdoch Children's Research Institute, an Australia-based child health research institute, partnered with Incepta Pharmaceuticals Limited to improve access to rotavirus vaccines. The collaboration between MCRI and Incepta Pharmaceuticals is designed to advance the protection of children against rotavirus by developing and distributing effective vaccines. This partnership is dedicated to expanding access to critical rotavirus vaccines, targeting regions with high infection rates and limited healthcare resources. Incepta Pharmaceuticals Limited is a Bangladesh-based pharmaceutical company that is developing rotavirus vaccines.

Regional Insights

North America was the largest region in the rotavirus vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Rotavirus Vaccine Market?

The rotavirus vaccine market consists of sales of combination vaccines, vaccine delivery systems, vaccine doses, and packs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rotavirus Vaccine Market Report 2026?

The rotavirus vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rotavirus vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.